St. Jude investigators are sharing their WGS cancer data through the St. Jude Cloud, as well as tools and pipelines to help other researchers analyze and use it.
The company is offering around 7.9 million shares of common stock at a price of $17 per share and is granting the underwriters an option to buy an additional 1.2 million shares.
Combined DNA/RNA-seq efforts in various settings could lead to new ways of treating kids with drugs meant for adults or to the development of new therapies.
During the five-year collaboration, the partners will research disease-causing gene mutations and develop new CRISPR-based technologies for drug discovery.
The company said the decrease was partially due to the impact on its clinical services business unit from the adoption of new revenues recognition standards.
The firm said revenues from its precision oncology business increased 98 percent in Q4, driven by higher testing volume and increased revenue per test.
